Showing results (1291-1300 of 1,805) with videos related to

Sort By:
Pageof 181
Experimental Eye Research|June 30, 2026
Three-Dimensional Platform-Dependent Modulation of Stemness and EMT-Associated Gene Expression in Primary and Metastatic Uveal Melanoma ModelsRebecca J Wilson, Charmaine A Ramlogan-Steel, Sarah J Greenstein, et al.
Chemistry & Biology|November 22, 2005
Investigating beta-hydroxyenduracididine formation in the biosynthesis of the mannopeptimycinsBrad Haltli, Ying Tan, Nathan A Magarvey, et al.
Reproductive Biology|August 5, 2008
Decreased expression of pigment epithelium derived factor (PEDF), an inhibitor of angiogenesis, in placentas of unexplained stillbirthsBeth A Plunkett, Philip Fitchev, Jennifer A Doll, et al.
Archives of General Psychiatry|November 9, 2011
Personality disorders and the 3-year course of alcohol, drug, and nicotine use disordersDeborah Hasin, Miriam C Fenton, Andrew Skodol, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|December 6, 2018
Patients' Expectations for Longevity of Kidney TransplantMichelle Gruttadauria, Colin Dunn, Juan Lin, et al.
Archives of General Psychiatry|May 3, 2006
Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorderPhilip Shaw, Jason Lerch, Deanna Greenstein, et al.
Vision Research|July 19, 2005
Multifocal visual evoked potentials to cone specific stimuli in patients with retinitis pigmentosaK Holopigian, S M Shuwairi, V C Greenstein, et al.
Annals of Clinical and Laboratory Science|July 1, 1984
Characteristics and natural history of alloimmunization following HLA-matched leukocyte transfusion in Hunter's syndromeR K Kakaiya, R Greenstein, P T Pisciotto, et al.
Ophthalmology. Glaucoma|October 17, 2022
Combined Model of OCT Angiography and Structural OCT Parameters to Predict Paracentral Visual Field Loss in Primary Open-Angle GlaucomaChristine Xu, Chhavi Saini, Mengyu Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 2008
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomesOren Cahlon, Michael J Zelefsky, Alison Shippy, et al.
Pageof 181